- Merck’s Phase III MANEUVER trial of pimicotinib, developed by Abbisko, showed significant improvement in TGCT patients, with a 54% response rate vs. 3.2% for placebo.
Tue Nov 12 07:01:56 -0000 2024 UTC– Merck announced positive results from the Phase III MANEUVER trial of pimicotinib, showing significant improvement in TGCT patients’ outcomes. The drug met primary and secondary endpoints, demonstrating efficacy and tolerability.
Pimicotinib may offer a new systemic therapy option for TGCT, a rare joint tumor.
Pimicotinib, a CSF-1R inhibitor, improved pain and stiffness, was well-tolerated, and presents a new treatment option for TGCT, primarily affecting young adults.
The trial included diverse global participants and confirms previous Phase I findings. Merck aims to bring pimicotinib to market, addressing the unmet need for systemic TGCT treatment.